Research programme: anti-cancer therapeutics - Tailor Bio
Latest Information Update: 03 Nov 2025
At a glance
- Originator Tailor Bio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 03 Nov 2025 Early research in Cancer in United Kingdom (unspecified route) before November 2025 (Tailor Bio pipeline, November 2025)